期刊
EPILEPSY & BEHAVIOR
卷 18, 期 3, 页码 322-324出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.yebeh.2010.04.043
关键词
Lacosamide; Atrial fibrillation; Cardiac arrhythmia; Antiepileptic drug; Seizures
资金
- Salter Family Trust
- Marc and Terry Jacoby
- Robert and Linda Brill
- Lagermeier and Lester families
- Boston Scientific
- National Institutes of Health
- Epilepsy Therapy Project
- Epilepsy Foundation
Lacosamide (LCM) is a novel antiepileptic drug that exerts a strong antiepileptic effect via slow inactivation of voltage-gated sodium channels. LCM has been approved by the Food and Drug Administration for treatment of partial seizures at doses up to 400 mg/day. Clinical trials have employed doses up to 600 mg/day. LCM has been associated with atrial fibrillation at high doses (600 mg/day) in patients with diabetes who had risk factors for heart disease. To our knowledge, atrial flutter or atrial fibrillation has not been reported in people with epilepsy. We report atrial flutter/atrial fibrillation at high doses of LCM (600 mg/day) in a patient with epilepsy who had no significant risk factors for heart disease, which resolved following discontinuation of LCM. The literature regarding LCM-related cardiac death and arrhythmia is discussed. Physicians should be aware of the potential cardiac effects of this novel antiepileptic drug. (C) 2010 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据